An investigation on behalf of investors, who currently hold shares of Impax Laboratories Inc (NASDAQ:IPXL), was announced concerning whether the takeover of Impax Laboratories Inc is unfair to NASDAQ:IPXL stockholders.

The investigation by a law firm concerns whether certain officers and directors of Impax Laboratories Inc breached their fiduciary duties owed to NASDAQ:IPXL investors in connection with the proposed acquisition.

Impax Laboratories Inc announced that they have entered into a business combination in an all-stock transaction. As a result of the transaction, Amneal Holdings members will own approximately 75% and Impax Laboratories Inc (NASDAQ:IPXL) shareholders will own approximately 25% of the new company's pro forma shares on an as converted basis.

However, given that at least one analyst has set the high target price for NASDAQ:IPXL shares at $35.00 per share and given that NASDAQ:IPXL shares traded in the open market as recently as September 2017 as high as $23.80 per share, the investigation concerns whether the offer is unfair to NASDAQ:IPXL stockholders. More specifically, the investigation concerns whether the Impax Laboratories Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.